Streetbeat News

Analyst Ratings

WTW

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on Willis Towers Watson (NASDAQ:WTW) and lowers the price target from $249 to $243.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:42 pm

ABOS

BBIO

GP

Acumen Pharmaceuticals (ABOS) reported positive results from its Phase 1 study of ACU193 for early Alzheimer's disease. BridgeBio (BBIO) announced positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy. GreenPower Motor Co (GP) reported Q4 sales of $15.30M, beating estimates of $13.98M.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:41 pm

BRP

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on BRP Group (NASDAQ:BRP) but has lowered the price target from $33 to $29.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:41 pm

WRB

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on WR Berkley (NYSE:WRB) but lowers the price target from $77 to $76.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:40 pm

TRV

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on Travelers Companies (NYSE:TRV) and raises the price target from $183 to $185.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:39 pm

HIG

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Hartford Financial Services Group (HIG) but lowers the price target from $93 to $91.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:38 pm

CB

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Chubb (NYSE:CB) but has lowered the price target from $253 to $249.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:37 pm

ACGL

Wells Fargo analyst Elyse Greenspan maintains an Overweight rating on Arch Capital Group (NASDAQ:ACGL) and raises the price target from $83 to $90.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:37 pm

AIG

Wells Fargo analyst Elyse Greenspan maintains an Equal-Weight rating on American Intl Gr (AIG) and raises the price target from $60 to $61.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:36 pm

BBIO

PFE

BridgeBio Pharma Inc (BBIO) announced positive results from its ATTRibute-CM Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy. The study showed significant improvement in the primary endpoint and a survival rate of 81% versus placebo survival rate of 74%. The company also observed a 50% relative risk reduction in cardiovascular-related hospitalization. In comparison to Pfizer Inc's (PFE) Vyndaqel/Vyndamax, acoramidis showed a 42% greater increase in serum TTR levels and a 92% improvement in median NT-proBNP. BBIO plans to file a New Drug Application with the FDA by the end of 2023. BBIO shares are up 59.30% in premarket trading.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 12:31 pm